Systematic reviewindependent cross-checkabstract checked I-ODD-102 standard review

Lactic acidosis with metformin is rare, even with mild kidney disease

Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

Overview

Inzucchi SE et al.. JAMA 2014 · PMID 25536258 · DOI 10.1001/jama.2014.15298

About 3-10 cases per 100,000 patient-years, similar to the background rate in diabetes.

Does the study support the specific claim? No · Methodological quality: moderate

Study explained simply

What did the researchers want to find out?: Review the lactic acidosis risk of metformin in kidney disease.
How was the study done?: Systematic literature review, narrative synthesis.
How many people, animals or samples were studied?: 65 studies.
What was actually found?: Very low incidence; lactate not substantially raised at eGFR 30-60.
How large was the observed effect?: 3-10 per 100,000 person-years.
What do the results mean in everyday life?: Lactic acidosis is a rare event, not a regular effect of metformin.
What are the study's limitations?: No pooled analysis; few trials.
What does it say about Elawady's specific claim?: Refutes 'automatic' lactic acidosis.
Do the results apply to Germany and Europe?: High.
What can explicitly not be concluded from this study?: Exact risk in severe kidney failure.

Authors: Inzucchi SE et al.
Journal: JAMA
Year: 2014
Identifier: PMID 25536258 DOI 10.1001/jama.2014.15298
Verification: verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
Retracted: no
Corrections: none
Extent checked: abstract only
Conflicts of interest and funding: NIA/NIH grants listed in PubMed record; author disclosures not reviewed.

What is the risk of lactic acidosis with metformin in people with impaired kidney function?

Study design: Systematic review – Systematic review of pharmacokinetic studies, case series, cohort studies, meta-analyses and one trial
Population: People with type 2 diabetes, with and without chronic kidney disease
Country: International (MEDLINE/Cochrane, English language)
Period: 1950-June 2014
Sample size: 65 included articles (from 818 screened)
Inclusion and exclusion criteria: Excluded reviews, letters, case reports and small case series

Results: Metformin levels generally remain within the therapeutic range and lactate is not substantially increased in mild to moderate CKD (eGFR 30-60). Overall incidence of lactic acidosis in metformin users about 3 to 10 per 100,000 person-years, 'generally indistinguishable from the background rate' in people with diabetes. Use against renal guidance in up to 1 in 4 patients has mostly not been associated with increased lactic acidosis.
Absolute risks: About 3-10 per 100,000 person-years (0.03-0.10 per 1,000 person-years).
Authors' conclusion: Evidence supports cautious expansion of metformin use in mild to moderate CKD with dose reductions and monitoring of kidney function.

Orienting tool: AMSTAR 2
Type of assessment: simplified assessment (abstract only)
Full formal assessment: no
Overall risk of bias: some concerns
Rationale: No meta-analysis or formal risk-of-bias assessment reported in the abstract.

Incidence range 3-10/100,000 PY corresponds to 1 case per 10,000-33,000 person-years (stats/C-ODD-01.py).

Directly addresses how often metformin causes lactic acidosis; refutes 'automatic' occurrence.

Case reports and the eGFR<30 signal (I-ODD-101) show the risk is real in contraindicated settings.

High.

Consistent with Cochrane (I-ODD-08): lactic acidosis is rare and mostly linked to contraindications.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	moderate
Risk of bias	some concerns
Precision of results	moderate
Directness	direct
Reproducibility	replicated
Consistency with the overall evidence	consistent
Regional transferability	high
Adequacy of the interpretation (by the archive)	not applicable

Risk in advanced CKD without RCT data.